Q2 revenue grew 22% year-over-year, driven by strong Diagnostics and Data & Apps performance, with major pharma deals and FDA approvals setting up significant future revenue gains. The Personalis acquisition and new financing support continued growth and margin expansion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.